3 results
Primary Objective* To assess the safety, tolerability, and efficacy (in terms of change in DAS28 [using C-ReactiveProtein (CRP)] from baseline) of JNJ-38518168 at a dose of 100 mg/day for up to 12 weekscompared to placebo in subjects with active…
Study AimsPrimary Aim: This is a proof-of-concept study to evaluate the effect of ARA 290 in pain of patients with CRPS1 by means of once daily subcutaneous injection with ARA 290 for 4 weeks. Secondary Aims: * Assess the predictive effect of…
The objective of this first-in-human study is to evaluate the safety, feasibility and efficacy of Re-Cellularization via Electroporation Therapy (ReCET) by the (Endogenex system) combined with (GLP-1 receptor agonist) in subjects with insulin…